SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics $CAPR is trending due to anticipation surrounding the release of pivotal Phase 3 HOPE-3 study data for Duchenne Muscular Dystrophy. The community is buzzing with speculation about the results and potential for a short squeeze, while also debating the validity of past criticism from prominent short sellers. Some traders are setting very high price targets based on the potential for FDA approval and buyout prospects.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to reports of lowered AI software sales quotas, sparking concerns about AI leadership and competition from Google. The community is debating the impact on MSFT's AI strategy and its broader influence on the market, especially in relation to AI hardware players like NVDA. Some investors view this as a buying opportunity, while others express disappointment and question the company's current direction.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending due to a major government contract win for an autonomous border-protection drone system, sparking significant community excitement. Investors are actively discussing the potential impact of this contract on future growth, the company's position in the defense sector, and possible short squeezes. The contract news has reinforced optimism about Ondas's long-term prospects.

$SMOL is the first memecoin with a verified OnlyFans launched on Solana via pump.fun. It follows Smol, a rescued Alabama dachshund who survived hoarding, shelter hunger, and a 5-day post-spay escape before finding her forever home. Now pampered with treats and spa days, she shares wholesome content—no adult themes, just derpy faces, snack videos, and rescue love. $SMOL aims to normalize kindness and support animal welfare through the creator economy.

Smol Fans

$SMOL is trending as community members rally around its unique narrative: a rescue dog on OnlyFans supporting other rescue animals. With comparisons to early-stage $DOGE and a focus on community-driven growth, $SMOL is gaining attention as a potential leader in the memecoin space on the Solana network. The coin's organic growth and the team's dedication are key talking points driving interest.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards as investors react to news of a large share offering intended to fund the repurchase of convertible notes, with some fearing dilution. The community is debating the long-term implications of this financial move, with opinions divided on whether it's a strategic maneuver or a sign of balance sheet strain. Adding to the volatility, commentary from Jim Cramer on CNBC has further fueled debate and speculation around the stock's future.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending following a positive upgrade driven by anticipated data-center growth and its acquisition of Celestial AI, which is viewed as a strategic move into AI interconnectivity. The community is weighing whether to chase the breakout or await a potential pullback, while analysts are raising price targets. Upgrades and catalysts are aligning after earnings, with many feeling it's a good entry point.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing volatility as traders react to news of potential shifts in economic policy and the unwinding of certain trades. Community members are debating the implications of job data and potential interest rate cuts, while some express concerns about an AI bubble. Overall, the conversation revolves around uncertainty and potential market corrections amid existing economic conditions.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors discuss the potential implications of Marvell's acquisition of Celestial AI, a key POET customer, and the validation it provides for POET's photonic interposer technology. The community is speculating about increased demand for POET's products and potential acquisition by a larger player like Marvell or Broadcom, with some emphasizing the company's unique technology and strong cash position. Concerns remain around dilution and the company's ability to scale production.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing volatility amid discussions around AI's impact and reactions to economic data; Microsoft's influence on the market is a key talking point. Community sentiment seems divided as some anticipate a further pullback, while others suggest dip-buying opportunities, and speculate on a potential Santa rally. Broader market themes include rate cut expectations and concerns about an AI bubble.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. ($CLNN) is trending due to positive ALS biomarker data for their drug candidate CNM-Au8, reigniting community excitement around a potential accelerated approval filing with the FDA. Discussions revolve around whether the data package meets the FDA's criteria, with many highlighting statistically significant NfL reductions and biomarker concordance. Community members are closely watching for further company announcements and potential implications for ALS patients.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acadian Asset Management LLC Boosts Position in Anika Therapeutics Inc. $ANIK

Acadian Asset Management LLC lifted its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK - Free Report) by 6.7% in the second quarter, according to its most recent filing with the...

Anika Therapeutics (NASDAQ:ANIK) Upgraded at Wall Street Zen

Wall Street Zen upgraded Anika Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday...

Barrington Research Forecasts Strong Price Appreciation for Anika Therapeutics (NASDAQ:ANIK) Stock

Barrington Research increased their price target on shares of Anika Therapeutics from $15.00 to $16.00 and gave the company an "outperform" rating in a research note on Thursday...

Anika Therapeutics (NASDAQ:ANIK) Releases Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the...

Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates

Anika (ANIK) delivered earnings and revenue surprises of +100.00% and +0.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts See a 98.59% Upside in Anika (ANIK): Can the Stock Really Move This High?

The consensus price target hints at a 98.6% upside potential for Anika (ANIK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Anika (ANIK) Upgraded to Buy: Here's What You Should Know

Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of 0.00% and +4.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

ANIK
Anika Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ANIK News

ANIKAnika Therapeutics Inc.